AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

BioLineRx Ltd. Share Issue/Capital Change 2026

Jan 24, 2026

6692_rns_2026-01-24_dda309b5-24a5-47c7-92a6-f48a3054fab2.htm

Share Issue/Capital Change

Opens in your device viewer

Form S-8 false


�� "�	2 380
BIOLINE RX LTD
Corporation no: 513398750	8688
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	24/01/2026
	www.isa.gov.il			www.tase.co.il				Reference:	2026-02-009272	Time of broadcast: 18:37 18:37

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onForm S-8

S-8_23-Jan-26_isa.pdf



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: [email protected] Company site: www.biolinerx.com

Previous names of reporting entity:

Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1
Israel